FIELD: biotechnology, medicine, immunology. SUBSTANCE: invention relates to recombinant antibodies IL4 used for treatment of patients with disorders associated with functions of IL4. Invention involves chimeric and human antibodies IL4 Mab that are derivatives of highly effective antibodies Mab and containing their pharmaceutical compositions and methods of diagnosis and treatment. Advantage of invention consists of the development of antagonist of IL4 with high affinity that is able to decrease the level of eosinophilic inflammation. EFFECT: enhanced effectiveness of antagonist, valuable immunological properties. 25 cl, 3 tbl, 10 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) | 2003 |
|
RU2303461C9 |
| ANTI-CXCR4 ANTIBODIES FOR TREATMENT OF HIV INFECTION | 2010 |
|
RU2573902C2 |
| IMMUNOGLOBULINS | 2005 |
|
RU2404192C2 |
| NOVEL ANTI-IL13 ANTIBODIES AND USE THEREOF | 2004 |
|
RU2487887C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| BLOCKING ANTI-Dkk-1 ANTIBODIES AND APPLICATIONS THEREOF | 2010 |
|
RU2548817C2 |
| IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
| IMMUNOGLOBULINS K HUMAN CD52 | 2010 |
|
RU2603743C2 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
